Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Sponsor: Wugen, Inc.
Summary
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.
Official title: A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
OBSERVATIONAL
Enrollment
44
Start Date
2022-08-22
Completion Date
2037-07-01
Last Updated
2024-11-20
Healthy Volunteers
No
Interventions
Genetic: WU-CART-007
No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
Locations (5)
City of Hope
Duarte, California, United States
Childrens Hospital LA
Los Angeles, California, United States
Washington University
St Louis, Missouri, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Peter MacCullam Cancer Center
Melbourne, Australia